Victory Pharma Completes Acquisition of Assets of MiddleBrook Pharmaceuticals
Company Expands Product Portfolio, Adds Drug Delivery Technology
Victory Pharma, Inc. announced that it has completed the acquisition of substantially all of the assets of MiddleBrook Pharmaceuticals, Inc.
Through the acquisition, Victory Pharma has expanded its product portfolio with the addition of anti-infective products MOXATAG® and KEFLEX® as well as the PULSYS® drug delivery technology platform. The product additions complement Victory's current products, such as NAPRELAN®, which the company markets to primary care and specialist physicians.
"This acquisition reflects our strategy of leveraging our existing commercial infrastructure to expand our portfolio of marketed products," said Matt Heck, president and chief executive officer of Victory Pharma. "The addition of these products balances our portfolio nicely, as NAPRELAN's highest period of utilization is in the spring and summer, while MOXATAG's utilization peaks during the flu season. And we believe MOXATAG will substantially benefit from our management team's prior, successful experience marketing anti-infective products."
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.